X4 Pharmaceuticals Inc Cash Flow-to-Debt Ratio
X4 Pharmaceuticals Inc cash flow-to-debt ratio. X4 Pharmaceuticals Inc (XFOR) has a Cash Flow-to-Debt Ratio of -0.21x as of June 2026, meaning its operating cash flow of $-20.79 Million could theoretically repay 0% of its total liabilities ($97.61 Million) in one year. Check XFOR cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of X4 Pharmaceuticals Inc (2015–2025)
Cash flow-to-debt ratio of X4 Pharmaceuticals Inc from 2015 to 2025. Historical debt coverage capacity for X4 Pharmaceuticals Inc across 11 annual periods. Also explore X4 Pharmaceuticals Inc (XFOR) net asset momentum to track the company's year-over-year net asset growth rate.
X4 Pharmaceuticals Inc Cash Flow-to-Debt Ratio by Year (2015–2025)
X4 Pharmaceuticals Inc cash flow-to-debt ratio by year from 2015 to 2025. Year-by-year debt coverage analysis for X4 Pharmaceuticals Inc. For the full cash flow conversion analysis, see cash efficiency ratio of X4 Pharmaceuticals Inc.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.82x | $-85.62 Million | $104.17 Million | ▲ +22.0% |
| 2024 | -1.05x | $-130.90 Million | $124.30 Million | ▼ -4.9% |
| 2023 | -1.00x | $-96.51 Million | $96.16 Million | ▼ -6.1% |
| 2022 | -0.95x | $-77.10 Million | $81.53 Million | ▲ +29.6% |
| 2021 | -1.34x | $-70.91 Million | $52.76 Million | ▼ -14.4% |
| 2020 | -1.17x | $-58.82 Million | $50.07 Million | ▲ +23.1% |
| 2019 | -1.53x | $-48.05 Million | $31.48 Million | ▲ +13.5% |
| 2018 | -1.76x | $-25.42 Million | $14.40 Million | ▼ -42.8% |
| 2017 | -1.24x | $-27.87 Million | $22.55 Million | ▼ -39.0% |
| 2016 | -0.89x | $-21.64 Million | $24.33 Million | ▼ -14.2% |
| 2015 | -0.78x | $-10.82 Million | $13.88 Million | — |